Literature DB >> 7495526

The role of stereotactic radiation therapy in the management of children with brain tumors.

C M Lew1, B LaVally.   

Abstract

Conventional radiation therapy plays an important role in the management of intracranial tumors in children. For certain tumors radiation therapy serves as the primary mode of treatment, and for others it plays an adjuvant role with surgery and/or chemotherapy. Improvements in long-term survival rates have focused attention on the long-term sequelae of brain tumors and their treatment, and the sequelae, in turn, have become important targets for clinical investigation. Long-term side effects of particular concern in children include cranial nerve damage, memory and intellectual deficits, pituitary-hypothalamic dysfunction, demyelinization of brain tissue, and secondary malignancies. A new form of radiation therapy, stereotactic radiotherapy (SRT), merges the technologies of stereotactic surgery and conventional fractionated radiotherapy. The intent is to deliver maximum tumoricidal doses to the target while limiting the dose to normal surrounding brain tissue. The key feature of SRT is a noninvasive, relocatable immobilization system to assure accurate and reproducible positioning during planning and treatment. The headframes used for children have been modified to address their specific needs. The complexities of this process require careful preparation of patients and their families and the participation of many disciplines. Long-term follow-up will be essential to evaluate the effectiveness of this innovative treatment.

Entities:  

Mesh:

Year:  1995        PMID: 7495526     DOI: 10.1177/104345429501200407

Source DB:  PubMed          Journal:  J Pediatr Oncol Nurs        ISSN: 1043-4542            Impact factor:   1.636


  1 in total

1.  A psychoeducational intervention reduces the need for anesthesia during radiotherapy for young childhood cancer patients.

Authors:  Sonja Haeberli; Michael A Grotzer; Felix K Niggli; Markus A Landolt; Claudia Linsenmeier; Roland A Ammann; Nicole Bodmer
Journal:  Radiat Oncol       Date:  2008-06-04       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.